Press release
Anavex Announces Long-lasting Effect of ANAVEX®3-71 Preventing Cognitive Decline in a Transgenic Rat Model of Alzheimer’s Disease at AAIC 2022
ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment
About this update from Anavex Life Sciences Corp.
[{"type":"text","content":"ANAVEX®3-71 effect is supported by biomarkers: Decrease of extracellular A (Abeta) deposition and reduced pathological inflammatory glial cell recruitment towards hippocampal neurons (p ≤ 0.01)\nNEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced long-lasting effect of clinical drug candidate ANAVEX®3-71 in preventing cognitive decline in a transgenic rat model of Alzheimer’s disease at the Alzheimer’s Association International Conference (AAIC), taking place in San Diego, CA and virtually on July 31 – August 4, 2022. The poster presentation titled, “An M1/sigma-1 receptor agonist prevents cognitive deficits, reduces amyloid plaques and neuroinflammation in a transgenic rat model of Alzheimer’s amyloid pathology” is being presented by Chiara Orciani, Sonia Do Carmo, Morgan K Foret, Helene Hall, Quentin Bonomo, Agustina Lavagna, Chunwei Huang and A. Claudio Cuello from McGill University, Montreal, Canada. ANAVEX®3-71 (10 μg/kg) or control (saline) was administered orally once daily in pre-plaque McGill-R-Thy1-APP transgenic (Tg) rats (n=22) and wild-type (wt) rats (n=22) divided into four groups, for seven months. Subsequently, after one month of drug interruption, behavioral tests were performed: Novel Object Recognition, Morris Water Maze, and Social Preference. Biomarker analysis revealed that ANAVEX®3-71 prevents McGill-APP transgenic rats from increasing cortical (p ≤ 0.05) and hippocampal (p ≤ 0.01) extracellular Aβ deposition. ANAVEX®3-71 also significantly reduces microglia (p ≤ 0.05) and astrocytes (p ≤ 0.05) recruitment towards Aβ-burdened neurons in the hippocampus. In the Novel Object Recognition behavioral test, Tg control rats explored the novel object significantly less than wt control rats (p ≤ 0.01). The impairment in Tg rats was completely reversed with ANAVEX®3-71 (p ≤ 0.01). In the Morris Water Maze behavioral test, the rats showed significant differences in learning. Tg control rats required more time to find the hidden platform than wt control rats (p ≤ 0.01). Conver...